Laine Elliott Thomas
Professor of Biostatistics & Bioinformatics
Causal Inference, Heterogeneity of Treatment Effects, Observational Data, Time-varying Treatments, Real World Evidence
Current Appointments & Affiliations
- Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2022
- Associate Director, DCRI Biostatistics, Biostatistics & Bioinformatics, Basic Science Departments 2018
- Associate Chair for Diversity and Inclusion in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2020
- Member in the Duke Clinical Research Institute, Duke Clinical Research Institute, Institutes and Centers 2009
Contact Information
- 200 Morris Street, 7812 200 Morris, Durham, NC 27701
- Duke Box 3850, Durham, NC 27710
-
laine.thomas@duke.edu
(919) 684-1289
- Background
-
Education, Training, & Certifications
- Ph.D., North Carolina State University 2009
-
Previous Appointments & Affiliations
- Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2021 - 2022
- Associate Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2018 - 2020
- Assistant Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2009 - 2018
-
Leadership & Clinical Positions at Duke
- Associate Director, Biostatistics at the DCRI
- Expertise
-
Global Scholarship
-
Research
-
- Research
-
Selected Grants
- Integrated Biostatistical Training for CVD Research awarded by North Carolina State University 2022 - 2027
- Innovative Biostatistical Methods for Analysis and Assessment of Clinical Trials Augmented by Real World Data awarded by Burroughs Wellcome Fund 2021 - 2026
- New causal inference methods for cluster randomized trials with post-randomization selection awarded by Patient Centered Outcomes Research Institute 2020 - 2024
- Postdoctoral Training in Cardiovascular Clinical Research awarded by National Institutes of Health 2013 - 2024
- HERO Program, HERO Registry, HERO-HCQ Trial awarded by Patient Centered Outcomes Research Institute 2020 - 2023
- Methods for the Design and Conduct of Subgroup Analysis in Observational Studies awarded by Patient Centered Outcomes Research Institute 2019 - 2022
- CHAMP-HF awarded by Novartis Pharmaceuticals Corporation 2016 - 2022
- Hero Ancillary Study: The Nurse HERO Study awarded by Children's Hospital of Philadelphia 2021
- GARFIELD-Atrial Fibrillation Registry Research awarded by Thrombosis Research Institute 2016 - 2020
- Statistical Methods for Complex Data in Cardiovascular Disease awarded by North Carolina State University 2013 - 2018
- Matching Methods for Comparative Effectiveness Studies of Longitudinal Treatments awarded by Agency for Healthcare Research and Quality 2015 - 2017
- NCDR-ACTION awarded by American College of Cardiology Foundation 2008 - 2015
-
External Relationships
- AstraZeneca
- InQuera
- JAMA
- Merck
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Chen-Lim ML, McCabe MA, Xu H, Thomas LE, Forrest CB, Birnbaum S, et al. Experiences of U.S. Nurses Compared With Nonnurses in the First Year of COVID-19: Findings From a National Registry. Nurs Res. 2022 Nov;71(6):421–31.Full Text Link to Item
-
Pokorney SD, Berchuck SI, Chiswell K, Sun J-L, Thomas L, Jones WS, et al. Atrial branch coronary artery stenosis as a mechanism for atrial fibrillation. Heart Rhythm. 2022 Aug;19(8):1237–44.Full Text Link to Item
-
Bahit MC, Vora AN, Li Z, Wojdyla DM, Thomas L, Goodman SG, et al. Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial. Jama Cardiol. 2022 Jul 1;7(7):682–9.Full Text Link to Item
-
Chapman B, Hellkamp AS, Thomas LE, Albert NM, Butler J, Patterson JH, et al. Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HF. J Am Heart Assoc. 2022 Jun 20;11(12):e022889.Full Text Link to Item
-
Cheng C, Li F, Thomas LE, Li FF. Addressing Extreme Propensity Scores in Estimating Counterfactual Survival Functions via the Overlap Weights. Am J Epidemiol. 2022 May 20;191(6):1140–51.Full Text Link to Item
-
DeVore AD, Hellkamp AS, Thomas L, Albert NM, Butler J, Patterson JH, et al. The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from CHAMP-HF. Eur J Heart Fail. 2022 May;24(5):762–70.Full Text Link to Item
-
Wise LA, Thomas L, Anderson S, Baird DD, Anchan RM, Terry KL, et al. Route of myomectomy and fertility: a prospective cohort study. Fertil Steril. 2022 May;117(5):1083–93.Full Text Link to Item
-
Greene SJ, Butler J, Hellkamp AS, Spertus JA, Vaduganathan M, Devore AD, et al. Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. J Card Fail. 2022 Mar;28(3):370–84.Full Text Link to Item
-
Zhou T, Tong G, Li F, Thomas LE. PSweight: An R Package for Propensity ScoreWeighting Analysis. R Journal. 2022 Mar 1;14(1):282–99.Full Text
-
Harskamp RE, Fanaroff AC, Lopes RD, Wojdyla DM, Goodman SG, Thomas LE, et al. Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. J Am Coll Cardiol. 2022 Feb 8;79(5):417–27.Full Text Link to Item
-
DeVore AD, Hill CL, Thomas LE, Albert NM, Butler J, Patterson JH, et al. Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model. Esc Heart Fail. 2022 Feb;9(1):178–85.Full Text Link to Item
-
Vaduganathan M, Fonarow GC, Greene SJ, Devore AD, Albert NM, Duffy CI, et al. Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. J Card Fail. 2022 Feb;28(2):191–201.Full Text Link to Item
-
Farjat AE, Virdone S, Thomas LE, Kakkar AK, Pieper KS, Piccini JP. The importance of the design of observational studies in comparative effectiveness research: Lessons from the GARFIELD-AF and ORBIT-AF registries. Am Heart J. 2022 Jan;243:110–21.Full Text Link to Item
-
Rymer JA, Li S, Pun PH, Thomas L, Wang TY. Racial Disparities in Invasive Management for Patients With Acute Myocardial Infarction With Chronic Kidney Disease. Circ Cardiovasc Interv. 2022 Jan;15(1):e011171.Full Text Link to Item
-
Khan MS, Greene SJ, Hellkamp AS, DeVore AD, Shen X, Albert NM, et al. Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. Circ Heart Fail. 2021 Nov;14(11):e008351.Full Text Link to Item
-
Thomas LE, Navar AM, Pencina MJ. Extrapolating Survival From Randomized Clinical Trial Data-Possibilities and Caution. Jama Cardiol. 2021 Nov 1;6(11):1305–7.Full Text Link to Item
-
Tran AT, Fonarow GC, Arnold SV, Jones PG, Thomas LE, Hill CL, et al. Risk Adjustment Model for Preserved Health Status in Patients With Heart Failure and Reduced Ejection Fraction: The CHAMP-HF Registry. Circ Cardiovasc Qual Outcomes. 2021 Oct;14(10):e008072.Full Text Link to Item
-
Yang S, Li F, Thomas LE. Covariate adjustment in subgroup analyses of randomized clinical trials: A propensity score approach. Clin Trials. 2021 Oct;18(5):570–81.Full Text Link to Item
-
Etherton MR, Shah S, Haolin X, Xian Y, Maisch L, Hannah D, et al. Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors. Stroke Vasc Neurol. 2021 Sep;6(3):384–94.Full Text Link to Item
-
Jackson LR, Schrader P, Thomas L, Steinberg BA, Blanco R, Allen LA, et al. Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). Am J Cardiovasc Drugs. 2021 Sep;21(5):553–61.Full Text Link to Item
-
Yang S, Lorenzi E, Papadogeorgou G, Wojdyla DM, Li F, Thomas LE. Propensity score weighting for causal subgroup analysis. Stat Med. 2021 Aug 30;40(19):4294–309.Full Text Link to Item
-
Thomas LE, Turakhia MP, Pencina MJ. Competing Risks, Treatment Switching, and Informative Censoring. Jama Cardiol. 2021 Aug 1;6(8):871–3.Full Text Link to Item
-
Lopes RD, Thomas L, Di Fusco M, Keshishian A, Luo X, Li X, et al. Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease. Am J Cardiol. 2021 Jun 1;148:69–77.Full Text Link to Item
-
Forrest CB, Xu H, Thomas LE, Webb LE, Cohen LW, Carey TS, et al. Impact of the Early Phase of the COVID-19 Pandemic on US Healthcare Workers: Results from the HERO Registry. J Gen Intern Med. 2021 May;36(5):1319–26.Full Text Link to Item
-
Albert NM, Tyson RJ, Hill CL, DeVore AD, Spertus JA, Duffy C, et al. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. Am Heart J. 2021 May;235:82–96.Full Text Link to Item
-
Greene SJ, Butler J, Spertus JA, Hellkamp AS, Vaduganathan M, DeVore AD, et al. Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. Jama Cardiol. 2021 May 1;6(5):522–31.Full Text Link to Item
-
Shen L, Xian Y, Chen AY, Thomas L, Roe MT, Peterson ED, et al. Effect of intervention timing on one-year mortality in elderly non-ST-segment elevation myocardial infarction patients. Coron Artery Dis. 2021 Mar 1;32(2):138–44.Full Text Link to Item
-
Wegienka G, Stewart EA, Nicholson WK, Zhang S, Li F, Thomas L, et al. Black Women Are More Likely Than White Women to Schedule a Uterine-Sparing Treatment for Leiomyomas. J Womens Health (Larchmt). 2021 Mar;30(3):355–66.Full Text Link to Item
-
Khariton Y, Fonarow GC, Hellkamp A, Thomas L, Nassif ME, Butler J, et al. Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP-HF registry. Esc Heart Fail. 2021 Feb;8(1):710–3.Full Text Link to Item
-
Li F, Thomas LE. RE:"ADDRESSING EXTREME PROPENSITY SCORES VIA THE OVERLAP WEIGHTS". Am J Epidemiol. 2021 Jan 4;190(1):189–90.Full Text Link to Item
-
Wosik J, Clowse MEB, Overton R, Adagarla B, Economou-Zavlanos N, Cavalier J, et al. Impact of the COVID-19 pandemic on patterns of outpatient cardiovascular care. Am Heart J. 2021 Jan;231:1–5.Full Text Link to Item
-
Srivastava PK, DeVore AD, Hellkamp AS, Thomas L, Albert NM, Butler J, et al. Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients. Jacc Heart Fail. 2021 Jan;9(1):28–38.Full Text Link to Item
-
Mentz RJ, Xu H, O’Brien EC, Thomas L, Alexy T, Gupta B, et al. PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure. Am Heart J. 2020 Dec;230:35–43.Full Text Link to Item
-
Zhou Y, Matsouaka RA, Thomas L. Propensity score weighting under limited overlap and model misspecification. Stat Methods Med Res. 2020 Dec;29(12):3721–56.Full Text Open Access Copy Link to Item
-
Thomas LE, Bonow RO, Pencina MJ. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19). Jama Cardiol. 2020 Sep 1;5(9):988–90.Full Text Link to Item
-
Jackson LR, Kim S, Blanco R, Thomas L, Ansell J, Fonarow GC, et al. Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J. 2020 Aug;226:85–93.Full Text Link to Item
-
Thomas LE, Yang S, Wojdyla D, Schaubel DE. Matching with time-dependent treatments: A review and look forward. Stat Med. 2020 Jul 30;39(17):2350–70.Full Text Link to Item
-
DeVore AD, Hellkamp AS, Thomas L, Albert NM, Butler J, Patterson JH, et al. Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HF. Circ Heart Fail. 2020 Jul;13(7):e006833.Full Text Link to Item
-
Thomas LE, Li F, Pencina MJ. Overlap Weighting: A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial. Jama. 2020 Jun 16;323(23):2417–8.Full Text Link to Item
-
Vaduganathan M, Fonarow GC, Greene SJ, DeVore AD, Kavati A, Sikirica S, et al. Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry. Jacc Heart Fail. 2020 Jun;8(6):469–80.Full Text Link to Item
-
Alexander JH, Wojdyla D, Vora AN, Thomas L, Granger CB, Goodman SG, et al. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. Circulation. 2020 May 19;141(20):1618–27.Full Text Link to Item
-
Thomas LE, Bonow RO, Pencina MJ. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19). Jama Cardiol. 2020 May 5;Full Text Link to Item
-
Laughlin-Tommaso SK, Lu D, Thomas L, Diamond M, Wallace K, Wegienka G, et al. Short-term quality of life after myomectomy for uterine fibroids from the compare-uf fibroid registry. Obstetrical and Gynecological Survey. 2020 May 1;75(5):285–7.Full Text
-
Laughlin-Tommaso SK, Lu D, Thomas L, Diamond MP, Wallace K, Wegienka G, et al. Short-term quality of life after myomectomy for uterine fibroids from the COMPARE-UF Fibroid Registry. Am J Obstet Gynecol. 2020 Apr;222(4):345.e1-345.e22.Full Text Link to Item
-
Pokorney SD, Black-Maier E, Hellkamp AS, Friedman DJ, Vemulapalli S, Granger CB, et al. Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal Disease. J Am Coll Cardiol. 2020 Mar 24;75(11):1299–308.Full Text Link to Item
-
Lopes RD, Leonardi S, Wojdyla DM, Vora AN, Thomas L, Storey RF, et al. Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. Circulation. 2020 Mar 3;141(9):781–3.Full Text Link to Item
-
Wallace K, Zhang S, Thomas L, Stewart EA, Nicholson WK, Wegienka GR, et al. Comparative effectiveness of hysterectomy versus myomectomy on one-year health-related quality of life in women with uterine fibroids. Fertil Steril. 2020 Mar;113(3):618–26.Full Text Link to Item
-
Thomas L, Li F, Pencina M. Using Propensity Score Methods to Create Target Populations in Observational Clinical Research. Jama. 2020 Feb 4;323(5):466–7.Full Text Link to Item
-
Pokorney SD, Holmes DN, Shrader P, Thomas L, Fonarow GC, Mahaffey KW, et al. Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. Am Heart J. 2020 Feb;220:145–54.Full Text Link to Item
-
Loring Z, Shrader P, Allen LA, Blanco R, Chan PS, Ezekowitz MD, et al. Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. Am Heart J. 2020 Jan;219:21–30.Full Text Link to Item
-
Vaduganathan M, Fonarow GC, Greene SJ, DeVore AD, Albert NM, Duffy CI, et al. Health-Related Quality of Life in Comorbid Heart Failure With Reduced Ejection Fraction and Diabetes Mellitus. J Am Coll Cardiol. 2019 Dec 24;74(25):3176–8.Full Text Link to Item
-
Giblin EM, Adams KF, Hill L, Fonarow GC, Williams FB, Sharma PP, et al. Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). Am J Cardiol. 2019 Dec 15;124(12):1900–6.Full Text Link to Item
-
Zullig LL, Jazowski SA, Wang TY, Hellkamp A, Wojdyla D, Thomas L, et al. Novel application of approaches to predicting medication adherence using medical claims data. Health Serv Res. 2019 Dec;54(6):1255–62.Full Text Link to Item
-
Khariton Y, Fonarow GC, Arnold SV, Hellkamp A, Nassif ME, Sharma PP, et al. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. Jacc Heart Fail. 2019 Nov;7(11):933–41.Full Text Link to Item
-
Rymer JA, Chen AY, Thomas L, Fonarow GC, Peterson ED, Wang TY. Readmissions After Acute Myocardial Infarction: How Often Do Patients Return to the Discharging Hospital? J Am Heart Assoc. 2019 Oct;8(19):e012059.Full Text Link to Item
-
Xian Y, Xu H, O’Brien EC, Shah S, Thomas L, Pencina MJ, et al. Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke: Findings From the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. Jama Neurol. 2019 Oct 1;76(10):1192–202.Full Text Open Access Copy Link to Item
-
Fanaroff AC, Vora AN, Chen AY, Mathews R, Udell JA, Roe MT, et al. Hospital participation in clinical trials for patients with acute myocardial infarction: Results from the National Cardiovascular Data Registry. Am Heart J. 2019 Aug;214:184–93.Full Text Link to Item
-
Nicholson WK, Wegienka G, Zhang S, Wallace K, Stewart E, Laughlin-Tommaso S, et al. Short-Term Health-Related Quality of Life After Hysterectomy Compared With Myomectomy for Symptomatic Leiomyomas. Obstet Gynecol. 2019 Aug;134(2):261–9.Full Text Link to Item
-
Pokorney SD, Holmes DN, Thomas L, Fonarow GC, Kowey PR, Reiffel JA, et al. Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. Jama Cardiol. 2019 Aug 1;4(8):756–64.Full Text Link to Item
-
Guimarães PO, Lopes RD, Alexander JH, Thomas L, Hellkamp AS, Hijazi Z, et al. International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin. J Thromb Thrombolysis. 2019 Jul;48(1):27–34.Full Text Link to Item
-
Thomas M, Khariton Y, Fonarow GC, Arnold SV, Hill L, Nassif ME, et al. Association of Changes in Heart Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP-HF. Jacc Heart Fail. 2019 Jul;7(7):615–25.Full Text Link to Item
-
Shavadia JS, Holmes DN, Thomas L, Peterson ED, Granger CB, Roe MT, et al. Comparative Effectiveness of β-Blocker Use Beyond 3 Years After Myocardial Infarction and Long-Term Outcomes Among Elderly Patients. Circ Cardiovasc Qual Outcomes. 2019 Jul;12(7):e005103.Full Text Link to Item
-
Thomas LE, O’Brien EC, Piccini JP, D’Agostino RB, Pencina MJ. Application of net reclassification index to non-nested and point-based risk prediction models: a review. Eur Heart J. 2019 Jun 14;40(23):1880–7.Full Text Link to Item
-
Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, et al. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019 May 21;73(19):2365–83.Full Text Link to Item
-
Vemulapalli S, Inohara T, Kim S, Thomas L, Piccini JP, Patel MR, et al. Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry). Am J Cardiol. 2019 May 15;123(10):1628–36.Full Text Link to Item
-
Perino AC, Shrader P, Turakhia MP, Ansell JE, Gersh BJ, Fonarow GC, et al. Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF Registry. J Am Heart Assoc. 2019 May 7;8(9):e011205.Full Text Link to Item
-
Holmes DN, Piccini JP, Allen LA, Fonarow GC, Gersh BJ, Kowey PR, et al. Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score. Circ Cardiovasc Qual Outcomes. 2019 May;12(5):e005358.Full Text Link to Item
-
Madhavan M, Holmes DN, Piccini JP, Ansell JE, Fonarow GC, Hylek EM, et al. Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation. Am Heart J. 2019 May;211:77–89.Full Text Link to Item
-
Peri-Okonny PA, Mi X, Khariton Y, Patel KK, Thomas L, Fonarow GC, et al. Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry. Jacc Heart Fail. 2019 Apr;7(4):350–8.Full Text Link to Item
-
Thomas LE, Schulte PJ. Separating variability in healthcare practice patterns from random error. Stat Methods Med Res. 2019 Apr;28(4):1247–60.Full Text Link to Item
-
Doll JA, Hellkamp AS, Thomas L, Fonarow GC, Peterson E, Wang TY. The association of pre- and posthospital medication adherence in myocardial infarction patients. Am Heart J. 2019 Feb;208:74–80.Full Text Link to Item
-
O’Brien EC, Holmes DN, Thomas L, Singer DE, Fonarow GC, Mahaffey KW, et al. Incremental prognostic value of renal function for stroke prediction in atrial fibrillation. Int J Cardiol. 2019 Jan 1;274:152–7.Full Text Link to Item
-
Li F, Thomas LE. Addressing Extreme Propensity Scores via the Overlap Weights. Am J Epidemiol. 2019 Jan 1;188(1):250–7.Full Text Link to Item
-
Jackson LR, Kim S, Shrader P, Blanco R, Thomas L, Ezekowitz MD, et al. Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. J Thromb Thrombolysis. 2018 Nov;46(4):435–9.Full Text Link to Item
-
Arnold SV, Cohen DJ, Dai D, Jones PG, Li F, Thomas L, et al. Predicting Quality of Life at 1 Year After Transcatheter Aortic Valve Replacement in a Real-World Population. Circ Cardiovasc Qual Outcomes. 2018 Oct;11(10):e004693.Full Text Link to Item
-
Huffman MD, Thomas LE. Tools for Evaluating and Improving Causal Inference: Introducing JAMA Cardiology Readers to the Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I) Tool. Jama Cardiol. 2018 Oct 1;3(10):907.Full Text Link to Item
-
Washam JB, Holmes DN, Thomas LE, Pokorney SD, Hylek EM, Fonarow GC, et al. Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF. J Am Heart Assoc. 2018 Sep 18;7(18):e008928.Full Text Link to Item
-
Rymer JA, Chen AY, Thomas L, Stafford J, Enriquez JR, Goyal A, et al. Advanced Practice Provider Versus Physician-Only Outpatient Follow-Up After Acute Myocardial Infarction. J Am Heart Assoc. 2018 Sep 4;7(17):e008481.Full Text Link to Item
-
DeVore AD, Hill CL, Thomas L, Sharma PP, Albert NM, Butler J, et al. Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. Circ Heart Fail. 2018 Sep;11(9):e005400.Full Text Link to Item
-
O’Brien EC, Li S, Thomas L, Wang TY, Roe MT, Peterson ED. The impact of clinical vs administrative claims coding on hospital risk-adjusted outcomes. Clin Cardiol. 2018 Sep;41(9):1225–31.Full Text Link to Item
-
O’Brien EC, Holmes DN, Thomas LE, Fonarow GC, Allen LA, Gersh BJ, et al. Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. Circulation. 2018 Aug 28;138(9):889–97.Full Text Link to Item
-
Jackson LR, Kim S, Fonarow GC, Freeman JV, Gersh BJ, Go AS, et al. Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA2DS2-VASc Scores: Findings From the ORBIT-AF I and II Registries. J Am Heart Assoc. 2018 Aug 21;7(16):e008764.Full Text Open Access Copy Link to Item
-
Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. J Am Coll Cardiol. 2018 Jul 24;72(4):351–66.Full Text Link to Item
-
Stewart EA, Lytle BL, Thomas L, Wegienka GR, Jacoby V, Diamond MP, et al. The Comparing Options for Management: PAtient-centered REsults for Uterine Fibroids (COMPARE-UF) registry: rationale and design. Am J Obstet Gynecol. 2018 Jul;219(1):95.e1-95.e10.Full Text Link to Item
-
DeVore AD, Mi X, Thomas L, Sharma PP, Albert NM, Butler J, et al. Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. J Am Heart Assoc. 2018 Jun 12;7(12).Full Text Link to Item
-
O’Brien EC, Holmes DN, Thomas L, Fonarow GC, Kowey PR, Ansell JE, et al. Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT-AF. J Am Heart Assoc. 2018 Jun 9;7(12).Full Text Link to Item
-
Udell JA, Desai NR, Li S, Thomas L, de Lemos JA, Wright-Slaughter P, et al. Neighborhood Socioeconomic Disadvantage and Care After Myocardial Infarction in the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes. 2018 Jun;11(6):e004054.Full Text Link to Item
-
Khariton Y, Nassif ME, Thomas L, Fonarow GC, Mi X, DeVore AD, et al. Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure. Jacc Heart Fail. 2018 Jun;6(6):465–73.Full Text Link to Item
-
Fanaroff AC, Chen AY, Thomas LE, Pieper KS, Garratt KN, Peterson ED, et al. Risk Score to Predict Need for Intensive Care in Initially Hemodynamically Stable Adults With Non-ST-Segment-Elevation Myocardial Infarction. J Am Heart Assoc. 2018 May 25;7(11).Full Text Link to Item
-
Mathews R, Wang W, Kaltenbach LA, Thomas L, Shah RU, Ali M, et al. Hospital Variation in Adherence Rates to Secondary Prevention Medications and the Implications on Quality. Circulation. 2018 May 15;137(20):2128–38.Full Text Link to Item
-
Fudim M, Liu PR, Shrader P, Blanco RG, Allen LA, Fonarow GC, et al. Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry. J Am Heart Assoc. 2018 Apr 13;7(8).Full Text Link to Item
-
Khariton Y, Hernandez AF, Fonarow GC, Sharma PP, Duffy CI, Thomas L, et al. Health Status Variation Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF (Change the Management of Patients With Heart Failure) Registry. Circ Cardiovasc Qual Outcomes. 2018 Apr;11(4):e004668.Full Text Link to Item
-
Pokorney SD, Yen DC, Campbell KB, Allen LaPointe NM, Sheng S, Thomas L, et al. Dofetilide dose reductions and discontinuations in women compared with men. Heart Rhythm. 2018 Apr;15(4):478–84.Full Text Link to Item
-
Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Thomas L, Wojdyla DM, et al. Digoxin and Mortality in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018 Mar 13;71(10):1063–74.Full Text Link to Item
-
Shavadia JS, French W, Hellkamp AS, Thomas L, Bates ER, Manoukian SV, et al. Comprehensive electrocardiogram-to-device time for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: A report from the American Heart Association mission: Lifeline program. Am Heart J. 2018 Mar;197:9–17.Full Text Link to Item
-
Steinberg BA, Shrader P, Pieper K, Thomas L, Allen LA, Ansell J, et al. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). J Am Heart Assoc. 2018 Feb 16;7(4).Full Text Link to Item
-
Echouffo-Tcheugui JB, Shrader P, Thomas L, Piccini JP, Fonarow GC. Reply: Graphing Ratio Measures on Forest Plot. J Am Coll Cardiol. 2018 Feb 6;71(5):586.Full Text Link to Item
-
Wang WT, Hellkamp A, Doll JA, Thomas L, Navar AM, Fonarow GC, et al. Lipid Testing and Statin Dosing After Acute Myocardial Infarction. J Am Heart Assoc. 2018 Jan 25;7(3).Full Text Link to Item
-
Inohara T, Shrader P, Pieper K, Blanco RG, Thomas L, Singer DE, et al. Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry Study. Jama Cardiol. 2018 Jan 1;3(1):54–63.Full Text Link to Item
-
Kraus WE, Yates T, Tuomilehto J, Sun J-L, Thomas L, McMurray JJV, et al. Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial. Bmj Open Diabetes Res Care. 2018;6(1):e000523.Full Text Link to Item
-
Thomas KL, Jackson LR, Shrader P, Ansell J, Fonarow GC, Gersh B, et al. Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation). J Am Heart Assoc. 2017 Dec 22;6(12).Full Text Link to Item
-
Steinberg BA, Gao H, Shrader P, Pieper K, Thomas L, Camm AJ, et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J. 2017 Dec;194:132–40.Full Text Link to Item
-
Barnett AS, Kim S, Fonarow GC, Thomas LE, Reiffel JA, Allen LA, et al. Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines: Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation). Circ Arrhythm Electrophysiol. 2017 Nov;10(11).Full Text Link to Item
-
Xian Y, Thomas L, Liang L, Federspiel JJ, Webb LE, Bushnell CD, et al. Unexplained Variation for Hospitals' Use of Inpatient Rehabilitation and Skilled Nursing Facilities After an Acute Ischemic Stroke. Stroke. 2017 Oct;48(10):2836–42.Full Text Link to Item
-
Echouffo-Tcheugui JB, Shrader P, Thomas L, Gersh BJ, Kowey PR, Mahaffey KW, et al. Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry. J Am Coll Cardiol. 2017 Sep 12;70(11):1325–35.Full Text Link to Item
-
Pagidipati NJ, Hellkamp A, Thomas L, Gulati M, Peterson ED, Wang TY. Use of Prescription Smoking Cessation Medications After Myocardial Infarction Among Older Patients in Community Practice. Jama Cardiol. 2017 Sep 1;2(9):1040–2.Full Text Link to Item
-
Brennan JM, Thomas L, Cohen DJ, Shahian D, Wang A, Mack MJ, et al. Transcatheter Versus Surgical Aortic Valve Replacement: Propensity-Matched Comparison. J Am Coll Cardiol. 2017 Jul 25;70(4):439–50.Full Text Link to Item
-
DeVore AD, Thomas L, Albert NM, Butler J, Hernandez AF, Patterson JH, et al. Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry. Am Heart J. 2017 Jul;189:177–83.Full Text Link to Item
-
Melloni C, Shrader P, Carver J, Piccini JP, Thomas L, Fonarow GC, et al. Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. Eur Heart J Qual Care Clin Outcomes. 2017 Jul 1;3(3):192–7.Full Text Open Access Copy Link to Item
-
Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, et al. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J. 2017 Jul;189:40–7.Full Text Link to Item
-
Cherian TS, Shrader P, Fonarow GC, Allen LA, Piccini JP, Peterson ED, et al. Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]). Am J Cardiol. 2017 Jun 1;119(11):1763–9.Full Text Link to Item
-
Lopes RD, Guimarães PO, Kolls BJ, Wojdyla DM, Bushnell CD, Hanna M, et al. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. Blood. 2017 Jun 1;129(22):2980–7.Full Text Link to Item
-
Steinberg BA, Simon DN, Thomas L, Ansell J, Fonarow GC, Gersh BJ, et al. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). Am J Cardiol. 2017 May 15;119(10):1590–5.Full Text Link to Item
-
Bethel MA, Hyland KA, Chacra AR, Deedwania P, Fulcher GR, Holman RR, et al. Updated risk factors should be used to predict development of diabetes. J Diabetes Complications. 2017 May;31(5):859–63.Full Text Link to Item
-
Sharma A, de Souza Brito F, Sun J-L, Thomas L, Haffner S, Holman RR, et al. Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Am Heart J. 2017 Apr;186:73–82.Full Text Link to Item
-
Hess PL, Kim S, Fonarow GC, Thomas L, Singer DE, Freeman JV, et al. Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. Am J Med. 2017 Apr;130(4):449–56.Full Text Link to Item
-
Pokorney SD, Kim S, Thomas L, Fonarow GC, Kowey PR, Gersh BJ, et al. Cardioversion and subsequent quality of life and natural history of atrial fibrillation. American Heart Journal. 2017 Mar;185:59–66.Full Text
-
Westenbrink BD, Alings M, Granger CB, Alexander JH, Lopes RD, Hylek EM, et al. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. American Heart Journal. 2017 Mar;185:140–9.Full Text
-
Hu PT, Lopes RD, Stevens SR, Wallentin L, Thomas L, Alexander JH, et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. J Am Heart Assoc. 2017 Jan 17;6(1).Full Text Link to Item
-
Guimarães PO, Wojdyla DM, Alexander JH, Thomas L, Alings M, Flaker GC, et al. Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. Int J Cardiol. 2017 Jan 15;227:443–9.Full Text Link to Item
-
Pokorney SD, Miller AL, Chen AY, Thomas L, Fonarow GC, de Lemos JA, et al. Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. Circulation. 2017 Jan 3;135(1):38–47.Full Text Link to Item
-
Bettger JP, Thomas L, Liang L, Xian Y, Bushnell CD, Saver JL, et al. Hospital Variation in Functional Recovery After Stroke. Circ Cardiovasc Qual Outcomes. 2017 Jan;10(1).Full Text Link to Item
-
Fanaroff AC, Peterson ED, Chen AY, Thomas L, Doll JA, Fordyce CB, et al. Intensive Care Unit Utilization and Mortality Among Medicare Patients Hospitalized With Non-ST-Segment Elevation Myocardial Infarction. Jama Cardiol. 2017 Jan 1;2(1):36–44.Full Text Link to Item
-
Pandey A, Kim S, Moore C, Thomas L, Gersh B, Allen LA, et al. Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. Jacc Heart Fail. 2017 Jan;5(1):44–52.Full Text Link to Item
-
Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, et al. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. J Am Coll Cardiol. 2016 Dec 20;68(24):2597–604.Full Text Link to Item
-
Thomas LE, Pencina MJ. Do Not Over (P) Value Your Research Article. Jama Cardiol. 2016 Dec 1;1(9):1055.Full Text Link to Item
-
Randolph TC, Simon DN, Thomas L, Allen LA, Fonarow GC, Gersh BJ, et al. Patient factors associated with quality of life in atrial fibrillation. Am Heart J. 2016 Dec;182:135–43.Full Text Link to Item
-
Steinberg BA, Shrader P, Kim S, Thomas L, Fonarow GC, Ansell J, et al. How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2016 Nov;181:145–52.Full Text Link to Item
-
Pokorney SD, Shrader P, Thomas L, Fonarow GC, Kowey PR, Singer DE, et al. Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Circulation. 2016 Oct 11;134(15):1122–4.Full Text Link to Item
-
Edmund Anstey D, Li S, Thomas L, Wang TY, Wiviott SD. Race and Sex Differences in Management and Outcomes of Patients After ST-Elevation and Non-ST-Elevation Myocardial Infarct: Results From the NCDR. Clin Cardiol. 2016 Oct;39(10):585–95.Full Text Link to Item
-
Kontos MC, Wang TY, Chen AY, Bates ER, Dauerman HL, Henry TD, et al. The effect of high-risk ST elevation myocardial infarction transfer patients on risk-adjusted in-hospital mortality: A report from the American Heart Association Mission: Lifeline program. Am Heart J. 2016 Oct;180:74–81.Full Text Link to Item
-
Vora AN, Wang TY, Hellkamp AS, Thomas L, Henry TD, Goyal A, et al. Differences in Short- and Long-Term Outcomes Among Older Patients With ST-Elevation Versus Non-ST-Elevation Myocardial Infarction With Angiographically Proven Coronary Artery Disease. Circ Cardiovasc Qual Outcomes. 2016 Sep;9(5):513–22.Full Text Link to Item
-
Pokorney SD, Simon DN, Thomas L, Gersh BJ, Hylek EM, Piccini JP, et al. Stability of International Normalized Ratios in Patients Taking Long-term Warfarin Therapy. Jama. 2016 Aug 9;316(6):661–3.Full Text Link to Item
-
Sutton NR, Li S, Thomas L, Wang TY, de Lemos JA, Enriquez JR, et al. The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With the Guidelines (GWTG) Medicare-linked database. Am Heart J. 2016 Aug;178:65–73.Full Text Link to Item
-
Goldstein BA, Thomas L, Zaroff JG, Nguyen J, Menza R, Khush KK. Assessment of Heart Transplant Waitlist Time and Pre- and Post-transplant Failure: A Mixed Methods Approach. Epidemiology. 2016 Jul;27(4):469–76.Full Text Link to Item
-
Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. Bmj. 2016 Jun 15;353:i2868.Full Text Link to Item
-
Lopes RD, Rao M, Simon DN, Thomas L, Ansell J, Fonarow GC, et al. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. Am J Med. 2016 Jun;129(6):592-599.e1.Full Text Link to Item
-
Piccini JP, Simon DN, Steinberg BA, Thomas L, Allen LA, Fonarow GC, et al. Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men: Two-Year Results From the ORBIT-AF Registry. Jama Cardiol. 2016 Jun 1;1(3):282–91.Full Text Link to Item
-
Pandey A, Gersh BJ, McGuire DK, Shrader P, Thomas L, Kowey PR, et al. Association of Body Mass Index With Care and Outcomes in Patients With Atrial Fibrillation: Results From the ORBIT-AF Registry. Jacc Clin Electrophysiol. 2016 Jun;2(3):355–63.Full Text Link to Item
-
O’Brien EC, Kim S, Thomas L, Fonarow GC, Kowey PR, Mahaffey KW, et al. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry. J Am Heart Assoc. 2016 May 4;5(5).Full Text Open Access Copy Link to Item
-
Fordyce CB, Wang TY, Chen AY, Thomas L, Granger CB, Scirica BM, et al. Long-Term Post-Discharge Risks in Older Survivors of Myocardial Infarction With and Without Out-of-Hospital Cardiac Arrest. J Am Coll Cardiol. 2016 May 3;67(17):1981–90.Full Text Link to Item
-
Alexander JH, Thomas LE. Using Data to Guide Anticoagulation in Patients With Atrial Fibrillation: Does the Analysis Fit the Question? Jama Cardiol. 2016 May 1;1(2):121–2.Full Text Link to Item
-
Faridi KF, Peterson ED, McCoy LA, Thomas L, Enriquez J, Wang TY. Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction. Jama Cardiol. 2016 May 1;1(2):147–55.Full Text Link to Item
-
Gundlund A, Fosbøl EL, Kim S, Fonarow GC, Gersh BJ, Kowey PR, et al. Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J. 2016 May;175:28–35.Full Text Link to Item
-
Anderson ML, Nichol G, Dai D, Chan PS, Thomas L, Al-Khatib SM, et al. Association Between Hospital Process Composite Performance and Patient Outcomes After In-Hospital Cardiac Arrest Care. Jama Cardiol. 2016 Apr 1;1(1):37–45.Full Text Link to Item
-
Prates PRL, Williams JB, Mehta RH, Stevens SR, Thomas L, Smith PK, et al. Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate. Braz J Cardiovasc Surg. 2016 Apr;31(2):106–14.Full Text Open Access Copy Link to Item
-
Golwala H, Jackson LR, Simon DN, Piccini JP, Gersh B, Go AS, et al. Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. Am Heart J. 2016 Apr;174:29–36.Full Text Link to Item
-
Noheria A, Shrader P, Piccini JP, Fonarow GC, Kowey PR, Mahaffey KW, et al. Rhythm Control Versus Rate Control and Clinical Outcomes in Patients With Atrial Fibrillation: Results From the ORBIT-AF Registry. Jacc Clin Electrophysiol. 2016 Apr;2(2):221–9.Full Text Link to Item
-
Hess CN, Hellkamp AS, Roe MT, Thomas L, Scirica BM, Peng SA, et al. Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non-ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization. J Am Heart Assoc. 2016 Mar 14;5(3):e002784.Full Text Open Access Copy Link to Item
-
Vora AN, Peterson ED, Hellkamp AS, Sutton NR, Panacek E, Thomas L, et al. Care Transitions After Acute Myocardial Infarction for Transferred-In Versus Direct-Arrival Patients. Circ Cardiovasc Qual Outcomes. 2016 Mar;9(2):109–16.Full Text Link to Item
-
Fonarow GC, Liang L, Thomas L, Xian Y, Saver JL, Smith EE, et al. Assessment of Home-Time After Acute Ischemic Stroke in Medicare Beneficiaries. Stroke. 2016 Mar;47(3):836–42.Full Text Link to Item
-
Shah RU, de Lemos JA, Wang TY, Chen AY, Thomas L, Sutton NR, et al. Post-Hospital Outcomes of Patients With Acute Myocardial Infarction With Cardiogenic Shock: Findings From the NCDR. J Am Coll Cardiol. 2016 Feb 23;67(7):739–47.Full Text Link to Item
-
Jackson LR, Kim SH, Piccini JP, Gersh BJ, Naccarelli GV, Reiffel JA, et al. Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT-AF Registry. Clin Cardiol. 2016 Feb;39(2):119–25.Full Text Open Access Copy Link to Item
-
O’Brien EC, Thomas LE. Untangling the paradox: Obesity as prognostic marker in prevalent cardiovascular disease. Am Heart J. 2016 Feb;172:170–2.Full Text Link to Item
-
Durheim MT, Cyr DD, Lopes RD, Thomas LE, Tsuang WM, Gersh BJ, et al. Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. Int J Cardiol. 2016 Jan 1;202:589–94.Full Text Link to Item
-
Xian Y, Federspiel JJ, Grau-Sepulveda M, Hernandez AF, Schwamm LH, Bhatt DL, et al. Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator. Jama Neurol. 2016 Jan;73(1):50–9.Full Text Open Access Copy Link to Item
-
Gruberg L, Hellkamp AS, Thomas LE, de Lemos JA, Scirica BM, Hilliard A, et al. The Association of Previous Revascularization With In-Hospital Outcomes in Acute Myocardial Infarction Patients: Results From the National Cardiovascular Data Registry. Jacc Cardiovasc Interv. 2015 Dec 28;8(15):1954–62.Full Text Link to Item
-
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. European Heart Journal. 2015 Dec 7;36(46):3258–64.Full Text
-
O’Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015 Dec 7;36(46):3258–64.Full Text Open Access Copy Link to Item
-
Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, et al. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. J Am Heart Assoc. 2015 Dec 1;4(12).Full Text Link to Item
-
Shen L, Shah BR, Li S, Thomas L, Wang TY, Alexander KP, et al. The Association of Transfer Rate From Hospitals Without Revascularization Capabilities and Mortality Risk for Older Non-ST-Segment Elevation Myocardial Infarction Patients. Clin Cardiol. 2015 Dec;38(12):733–9.Full Text Link to Item
-
Goyal A, de Lemos JA, Peng SA, Thomas L, Amsterdam EA, Hockenberry JM, et al. Association of Patient Enrollment in Medicare Part D With Outcomes After Acute Myocardial Infarction. Circ Cardiovasc Qual Outcomes. 2015 Nov;8(6):567–75.Full Text Link to Item
-
Doll JA, Hellkamp A, Thomas L, Ho PM, Kontos MC, Whooley MA, et al. Effectiveness of cardiac rehabilitation among older patients after acute myocardial infarction. Am Heart J. 2015 Nov;170(5):855–64.Full Text Link to Item
-
Enriquez JR, de Lemos JA, Parikh SV, Simon DN, Thomas LE, Wang TY, et al. Modest Associations Between Electronic Health Record Use and Acute Myocardial Infarction Quality of Care and Outcomes: Results From the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes. 2015 Nov;8(6):576–85.Full Text Link to Item
-
Steinberg BA, Kim S, Thomas L, Fonarow GC, Gersh BJ, Holmqvist F, et al. Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF). J Am Heart Assoc. 2015 Sep 14;4(9):e002031.Full Text Open Access Copy Link to Item
-
Preiss D, Thomas LE, Wojdyla DM, Haffner SM, Gill JMR, Yates T, et al. Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. Bmj Open. 2015 Aug 14;5(8):e007901.Full Text Link to Item
-
Hess CN, Peterson ED, Peng SA, de Lemos JA, Fosbol EL, Thomas L, et al. Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation. J Am Coll Cardiol. 2015 Aug 11;66(6):616–27.Full Text Link to Item
-
Yates T, Davies MJ, Haffner SM, Schulte PJ, Thomas L, Huffman KM, et al. Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial. Diabet Med. 2015 Aug;32(8):1090–6.Full Text Link to Item
-
O’Brien EC, McCoy LA, Thomas L, Peterson ED, Wang TY. Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines Registry. Am Heart J. 2015 Jul;170(1):55–61.Full Text Link to Item
-
Pokorney SD, Simon DN, Thomas L, Fonarow GC, Kowey PR, Chang P, et al. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J. 2015 Jul;170(1):141-148.e1.Full Text Link to Item
-
Freeman JV, Simon DN, Go AS, Spertus J, Fonarow GC, Gersh BJ, et al. Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes. 2015 Jul;8(4):393–402.Full Text Link to Item
-
Allen LA, Fonarow GC, Simon DN, Thomas LE, Marzec LN, Pokorney SD, et al. Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. J Am Coll Cardiol. 2015 Jun 30;65(25):2691–8.Full Text Link to Item
-
Pokorney SD, Miller AL, Chen AY, Thomas L, Fonarow GC, de Lemos JA, et al. Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. Jama. 2015 Jun 23;313(24):2433–40.Full Text Link to Item
-
Holmqvist F, Kim S, Steinberg BA, Reiffel JA, Mahaffey KW, Gersh BJ, et al. Heart rate is associated with progression of atrial fibrillation, independent of rhythm. Heart. 2015 Jun;101(11):894–9.Full Text Open Access Copy Link to Item
-
Lopes RD, Gharacholou SM, Holmes DN, Thomas L, Wang TY, Roe MT, et al. Cumulative incidence of death and rehospitalization among the elderly in the first year after NSTEMI. Am J Med. 2015 Jun;128(6):582–90.Full Text Link to Item
-
Held C, Hylek EM, Alexander JH, Hanna M, Lopes RD, Wojdyla DM, et al. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J. 2015 May 21;36(20):1264–72.Full Text Link to Item
-
Allen LaPointe NM, Dai D, Thomas L, Piccini JP, Peterson ED, Al-Khatib SM. Comparisons of hospitalization rates among younger atrial fibrillation patients receiving different antiarrhythmic drugs. Circ Cardiovasc Qual Outcomes. 2015 May;8(3):292–300.Full Text Link to Item
-
Kontos MC, Scirica BM, Chen AY, Thomas L, Anderson ML, Diercks DB, et al. Cardiac arrest and clinical characteristics, treatments and outcomes among patients hospitalized with ST-elevation myocardial infarction in contemporary practice: A report from the National Cardiovascular Data Registry. Am Heart J. 2015 Apr;169(4):515-22.e1.Full Text Link to Item
-
Granger CB, Lopes RD, Hanna M, Ansell J, Hylek EM, Alexander JH, et al. Erratum: Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the ARISTOTLE trial (American Heart Journal (2014) 169:1 (2530) DOI: 10.1016/j.ahj.2014.09.006). American Heart Journal. 2015 Apr 1;169(4):594.Full Text
-
Katz M, Califf RM, Sun J-L, McMurray JJV, Thomas L, Lopes RD. Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial. Am J Med. 2015 Mar;128(3):297–302.Full Text Link to Item
-
Steinberg BA, Peterson ED, Kim S, Thomas L, Gersh BJ, Fonarow GC, et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation. 2015 Feb 3;131(5):488–94.Full Text Open Access Copy Link to Item
-
Karrowni W, Wang TY, Chen AY, Thomas L, Saucedo JF, El Accaoui RN. Chronic vitamin K antagonist therapy and bleeding risk in ST elevation myocardial infarction patients. Heart. 2015 Feb;101(4):264–70.Full Text Link to Item
-
Vora AN, Holmes DN, Rokos I, Roe MT, Granger CB, French WJ, et al. Fibrinolysis use among patients requiring interhospital transfer for ST-segment elevation myocardial infarction care: a report from the US National Cardiovascular Data Registry. Jama Intern Med. 2015 Feb;175(2):207–15.Full Text Link to Item
-
Allen LaPointe NM, Dai D, Thomas L, Piccini JP, Peterson ED, Al-Khatib SM. Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease. Am J Cardiol. 2015 Feb 1;115(3):316–22.Full Text Link to Item
-
Fauchier L, Greenlaw N, Ferrari R, Ford I, Fox KM, Tardif J-C, et al. Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. Plos One. 2015;10(4):e0125164.Full Text Link to Item
-
Granger CB, Lopes RD, Hanna M, Ansell J, Hylek EM, Alexander JH, et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J. 2015 Jan;169(1):25–30.Full Text Link to Item
-
Holmqvist F, Kim S, Steinberg BA, Reiffel JA, Mahaffey KW, Gersh BJ, et al. Heart rate is associated with progression of atrial fibrillation, independent of rhythm. Heart. 2015;Full Text
-
Lytle BL, Li S, Lofthus DM, Thomas L, Poteat JL, Bhatt DL, et al. Targeted versus standard feedback: results from a randomized quality improvement trial. Am Heart J. 2015 Jan;169(1):132-41.e2.Full Text Link to Item
-
Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood. 2014 Dec 11;124(25):3692–8.Full Text Link to Item
-
Preiss D, Haffner SM, Thomas LE, Sun J-L, Sattar N, Yates T, et al. Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study. Diabetes Obes Metab. 2014 Dec;16(12):1265–8.Full Text Link to Item
-
Allen LA, Fonarow GC, Holmes DN, Thomas LE, Marzec LN, Pokorney SD, et al. Digoxin Use and Subsequent Outcomes Among Patients with and without Heart Failure in a Contemporary Atrial Fibrillation Cohort: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation. 2014 Nov 25;130.Link to Item
-
Rymer J, McCoy LA, Thomas L, Peterson ED, Wang TY. Persistence of evidence-based medication use after discharge from academic versus nonacademic hospitals among patients with non-ST-segment elevation myocardial infarction. Am J Cardiol. 2014 Nov 15;114(10):1479–84.Full Text Link to Item
-
Thomas KL, Shah BR, Elliot-Bynum S, Thomas KD, Damon K, Allen LaPointe NM, et al. Check it, change it: a community-based, multifaceted intervention to improve blood pressure control. Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):828–34.Full Text Link to Item
-
de Barros e Silva PGM, Califf RM, Sun J-L, McMurray JJV, Holman R, Haffner S, et al. Chronic obstructive pulmonary disease and cardiovascular risk: insights from the NAVIGATOR trial. Int J Cardiol. 2014 Oct 20;176(3):1126–8.Full Text Link to Item
-
Flaker G, Lopes RD, Hylek E, Wojdyla DM, Thomas L, Al-Khatib SM, et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol. 2014 Oct 14;64(15):1541–50.Full Text Link to Item
-
O’Brien EC, Simon DN, Allen LA, Singer DE, Fonarow GC, Kowey PR, et al. Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014 Oct;168(4):487–94.Full Text Link to Item
-
Mathews R, Chen AY, Thomas L, Wang TY, Chin CT, Thomas KL, et al. Differences in short-term versus long-term outcomes of older black versus white patients with myocardial infarction: findings from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of American College of Cardiology/American Heart Association Guidelines (CRUSADE). Circulation. 2014 Aug 19;130(8):659–67.Full Text Link to Item
-
Steinberg BA, Blanco RG, Ollis D, Kim S, Holmes DN, Kowey PR, et al. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. Am Heart J. 2014 Aug;168(2):160–7.Full Text Link to Item
-
Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014 Jul 21;35(28):1864–72.Full Text Link to Item
-
Beatty AL, Li S, Thomas L, Amsterdam EA, Alexander KP, Whooley MA. Trends in referral to cardiac rehabilitation after myocardial infarction: data from the National Cardiovascular Data Registry 2007 to 2012. J Am Coll Cardiol. 2014 Jun 17;63(23):2582–3.Full Text Link to Item
-
Shen L, Thomas L, Shah BR. Response to letter to the editor by Lin et al. Am Heart J. 2014 Jun;167(6):e21.Full Text Link to Item
-
Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol. 2014 May 27;63(20):2141–7.Full Text Link to Item
-
Steinberg BA, Kim S, Thomas L, Fonarow GC, Hylek E, Ansell J, et al. Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation. 2014 May 20;129(20):2005–12.Full Text Link to Item
-
O’Brien E, Subherwal S, Roe MT, Holmes DN, Thomas L, Alexander KP, et al. Do patients treated at academic hospitals have better longitudinal outcomes after admission for non-ST-elevation myocardial infarction? Am Heart J. 2014 May;167(5):762–9.Full Text Link to Item
-
Steinberg BA, Kim S, Fonarow GC, Thomas L, Ansell J, Kowey PR, et al. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014 May;167(5):735-42.e2.Full Text Link to Item
-
Huffman KM, Sun J-L, Thomas L, Bales CW, Califf RM, Yates T, et al. Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR. Metabolism. 2014 Apr;63(4):554–61.Full Text Link to Item
-
Yates T, Haffner SM, Schulte PJ, Thomas L, Huffman KM, Bales CW, et al. Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. Lancet. 2014 Mar 22;383(9922):1059–66.Full Text Link to Item
-
Harskamp RE, Wang TY, Bhatt DL, Wiviott SD, Amsterdam EA, Li S, et al. Hospital patterns of medical management strategy use for patients with non-ST-elevation myocardial infarction and 3-vessel or left main coronary artery disease. Am Heart J. 2014 Mar;167(3):355-362.e3.Full Text Link to Item
-
Xian Y, Chen AY, Thomas L, Roe MT, Subherwal S, Cannon CP, et al. Sources of hospital-level variation in major bleeding among patients with non-st-segment elevation myocardial infarction: a report from the National Cardiovascular Data Registry (NCDR). Circ Cardiovasc Qual Outcomes. 2014 Mar;7(2):236–43.Full Text Link to Item
-
Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, et al. Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation". Circulation. 2014 Jan 14;129(2):e21–2.Full Text Link to Item
-
Alexander JH, Lopes RD, Thomas L, Alings M, Atar D, Aylward P, et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2014 Jan;35(4):224–32.Full Text Link to Item
-
Harskamp RE, Wang TY, Bhatt DL, Wiviott SD, Amsterdam EA, Li S, et al. Hospital patterns of medical management strategy use for patients with non-ST-elevation myocardial infarction and 3-vessel or left main coronary artery disease. American Heart Journal. 2014;167(3):355-362.e3.
-
Shen L, Shah BR, Reyes EM, Thomas L, Wojdyla D, Diem P, et al. Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. Bmj. 2013 Dec 9;347:f6745.Full Text Link to Item
-
Shen L, Peterson ED, Li S, Thomas L, Alexander K, Xian Y, et al. The association between smoking and long-term outcomes after non-ST-segment elevation myocardial infarction in older patients. Am Heart J. 2013 Dec;166(6):1056–62.Full Text Link to Item
-
Steinberg BA, Holmes DN, Piccini JP, Ansell J, Chang P, Fonarow GC, et al. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc. 2013 Nov 25;2(6):e000535.Full Text Open Access Copy Link to Item
-
Fosbol EL, Wang TY, Li S, Piccini J, Lopes RD, Mills RM, et al. Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. Am Heart J. 2013 Nov;166(5):864–70.Full Text Link to Item
-
Latini R, Staszewsky L, Sun J-L, Bethel MA, Disertori M, Haffner SM, et al. Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. Am Heart J. 2013 Nov;166(5):935-40.e1.Full Text Link to Item
-
Shah BR, Thomas KL, Elliot-Bynum S, Thomas K, Damon K, Allen LaPointe N, et al. Check it, change it: a community-based intervention to improve blood pressure control. Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):741–8.Full Text Link to Item
-
Thomas L, Stefanski LA, Davidian M. Moment Adjusted Imputation for Multivariate Measurement Error Data with Applications to Logistic Regression. Comput Stat Data Anal. 2013 Nov 1;67:15–24.Full Text Link to Item
-
Hess CN, Shah BR, Peng SA, Thomas L, Roe MT, Peterson ED. Association of early physician follow-up and 30-day readmission after non-ST-segment-elevation myocardial infarction among older patients. Circulation. 2013 Sep 10;128(11):1206–13.Full Text Link to Item
-
Garcia DA, Wallentin L, Lopes RD, Thomas L, Alexander JH, Hylek EM, et al. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J. 2013 Sep;166(3):549–58.Full Text Link to Item
-
Preiss D, Giles TD, Thomas LE, Sun J-L, Haffner SM, Holman RR, et al. Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. Stroke. 2013 Sep;44(9):2590–3.Full Text Link to Item
-
Steinberg BA, Kim S, Piccini JP, Fonarow GC, Lopes RD, Thomas L, et al. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2013 Aug 13;128(7):721–8.Full Text Link to Item
-
Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D, et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J. 2013 Aug;34(31):2464–71.Full Text Link to Item
-
Bagai A, Chen AY, Wang TY, Alexander KP, Thomas L, Ohman EM, et al. Long-term outcomes among older patients with non-ST-segment elevation myocardial infarction complicated by cardiogenic shock. Am Heart J. 2013 Aug;166(2):298–305.Full Text Link to Item
-
Fosbol EL, Holmes DN, Piccini JP, Thomas L, Reiffel JA, Mills RM, et al. Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry. J Am Heart Assoc. 2013 Jul 18;2(4):e000110.Full Text Open Access Copy Link to Item
-
Bethel MA, Chacra AR, Deedwania P, Fulcher GR, Holman RR, Jenssen T, et al. A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk. Am J Cardiol. 2013 Jul 15;112(2):231–7.Full Text Link to Item
-
Cullen MW, Kim S, Piccini JP, Ansell JE, Fonarow GC, Hylek EM, et al. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):461–9.Full Text Link to Item
-
Hess PL, Kim S, Piccini JP, Allen LA, Ansell JE, Chang P, et al. Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation. Am J Med. 2013 Jul;126(7):625-32.e1.Full Text Link to Item
-
Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013 Jun 4;127(22):2166–76.Full Text Link to Item
-
Chatterjee R, Thomas L, Svetkey L, Brancati FL, Califf RM, Edelman D. Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Am J Hypertens. 2013 Jun;26(6):723–6.Full Text Link to Item
-
Roe MT, Li S, Thomas L, Wang TY, Alexander KP, Ohman EM, et al. Long-term outcomes after invasive management for older patients with non-ST-segment elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2013 May 1;6(3):323–32.Full Text Link to Item
-
Manfredi JA, Al-Khatib SM, Shaw LK, Thomas L, Fogel RI, Padanilam B, et al. Association between left ventricular ejection fraction post-cardiac resynchronization treatment and subsequent implantable cardioverter defibrillator therapy for sustained ventricular tachyarrhythmias. Circ Arrhythm Electrophysiol. 2013 Apr;6(2):257–64.Full Text Link to Item
-
Fosbøl EL, Peterson ED, Weeke P, Wang TY, Mathews R, Kober L, et al. Spousal depression, anxiety, and suicide after myocardial infarction. Eur Heart J. 2013 Mar;34(9):649–56.Full Text Link to Item
-
Wong YW, Thomas L, Sun J-L, McMurray JJV, Krum H, Hernandez AF, et al. Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study. Circ Heart Fail. 2013 Mar;6(2):203–10.Full Text Link to Item
-
Thomas L, Peterson ED. Statistical analysis plans in observational research--reply. Jama. 2013 Jan 2;309(1):32.Full Text Link to Item
-
Leonardi S, Thomas L, Neely ML, Tricoci P, Lopes RD, White HD, et al. Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction. J Am Coll Cardiol. 2012 Dec 4;60(22):2296–304.Full Text Link to Item
-
Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012 Nov;33(22):2821–30.Full Text Link to Item
-
Thomas L, Peterson ED. The value of statistical analysis plans in observational research: defining high-quality research from the start. Jama. 2012 Aug 22;308(8):773–4.Full Text Link to Item
-
Lopes RD, Subherwal S, Holmes DN, Thomas L, Wang TY, Rao SV, et al. The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction. Eur Heart J. 2012 Aug;33(16):2044–53.Full Text Link to Item
-
Subherwal S, Bhatt DL, Li S, Wang TY, Thomas L, Alexander KP, et al. Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):541–9.Full Text Link to Item
-
Subherwal S, Peterson ED, Dai D, Thomas L, Messenger JC, Xian Y, et al. Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data CathPCI Registry. J Am Coll Cardiol. 2012 May 22;59(21):1861–9.Full Text Link to Item
-
Fosbol EL, Wang TY, Li S, Piccini JP, Lopes RD, Shah B, et al. Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction. Am Heart J. 2012 Apr;163(4):720–8.Full Text Link to Item
-
Kociol RD, Lopes RD, Clare R, Thomas L, Mehta RH, Kaul P, et al. International variation in and factors associated with hospital readmission after myocardial infarction. Jama. 2012 Jan 4;307(1):66–74.Full Text Link to Item
-
Samsa GP, Thomas L, Lee LS, Neal EM. An active learning approach to teach advanced multi-predictor modeling concepts to clinicians. Journal of Statistics Education. 2012 Jan 1;20(1):1–34.Full Text
-
Preiss D, Thomas LE, Sun J-L, Haffner SM, Holman RR, Standl E, et al. Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. Bmj Open. 2012;2(6).Full Text Link to Item
-
Thomas L, Stefanski L, Davidian M. A moment-adjusted imputation method for measurement error models. Biometrics. 2011 Dec;67(4):1461–70.Full Text Link to Item
-
Roe MT, Chen AY, Thomas L, Wang TY, Alexander KP, Hammill BG, et al. Predicting long-term mortality in older patients after non-ST-segment elevation myocardial infarction: the CRUSADE long-term mortality model and risk score. Am Heart J. 2011 Nov;162(5):875-883.e1.Full Text Link to Item
-
Piccini JP, Fraulo ES, Ansell JE, Fonarow GC, Gersh BJ, Go AS, et al. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J. 2011 Oct;162(4):606-612.e1.Full Text Link to Item
-
Britton KA, Aggarwal V, Chen AY, Alexander KP, Amsterdam E, Fraulo E, et al. No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and acute myocardial infarction. Am Heart J. 2011 Apr;161(4):657-663.e1.Full Text Link to Item
-
Fiuzat M, Shaw LK, Thomas L, Felker GM, O’Connor CM. United States stock market performance and acute myocardial infarction rates in 2008-2009 (from the Duke Databank for Cardiovascular Disease). Am J Cardiol. 2010 Dec 1;106(11):1545–9.Full Text Link to Item
-
Berger JS, Elliott L, Gallup D, Roe M, Granger CB, Armstrong PW, et al. Sex differences in mortality following acute coronary syndromes. Jama. 2009 Aug 26;302(8):874–82.Full Text Link to Item
-
Ashley-Koch AE, Elliott L, Kail ME, De Castro LM, Jonassaint J, Jackson TL, et al. Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease. Blood. 2008 Jun 15;111(12):5721–6.Full Text Link to Item
-
DREAM Trial Investigators, Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care. 2008 May;31(5):1007–14.Full Text Link to Item
-
Elliott L, Ashley-Koch AE, De Castro L, Jonassaint J, Price J, Ataga KI, et al. Genetic polymorphisms associated with priapism in sickle cell disease. Br J Haematol. 2007 May;137(3):262–7.Full Text Link to Item
-
DREAM Trial Investigators, Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006 Oct 12;355(15):1551–62.Full Text Link to Item
-
-
Conference Papers
-
Thomas M, Khariton Y, Fonarow GC, Arnold SV, Hill L, Nassif ME, et al. Association between sacubitril/valsartan initiation and real-world health status trajectories over 18 months in heart failure with reduced ejection fraction. In: Esc Heart Failure. 2021. p. 2670–8.Full Text
-
Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, et al. Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. In: Am J Med. 2017. p. 1440-1448.e1.Full Text Link to Item
-
Piccini J, Washam JB, Simon DN, Thomas LE, Hylek EM, Fonarow GC, et al. Pharmacotherapy for atrial fibrillation in patients with chronic kidney disease: insights from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT AF). In: European Heart Journal. OXFORD UNIV PRESS; 2016. p. 685–685.Link to Item
-
Pokorney SD, Simon DN, Thomas LE, Fonarow GC, Mahaffey KW, Gersh BJ, et al. Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT AF). In: European Heart Journal. OXFORD UNIV PRESS; 2016. p. 686–686.Link to Item
-
Noheria A, Shrader P, Piccini JP, Fonarow GC, Kowey PR, Mahaffey KW, et al. Rhythm Control Versus Rate Control and Clinical Outcomes in Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2015.Link to Item
-
Durheim MT, Cyr DD, Al-Khatib SM, Thomas LE, Lopes RD, Gersh BJ, et al. Chronic Obstructive Pulmonary Disease Is Associated With Increased Risk Of Mortality Among Patients With Atrial Fibrillation: Insights From The Aristotle Trial. In: American Journal of Respiratory and Critical Care Medicine. AMER THORACIC SOC; 2015.Link to Item
-
-
- Teaching & Mentoring
-
Recent Courses
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.